[HTML][HTML] Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma
…, J Hubert, M Gross-Goupil, JC Bernhard… - … England Journal of …, 2018 - Mass Medical Soc
Background Cytoreductive nephrectomy has been the standard of care in metastatic renal-cell
carcinoma for 20 years, supported by randomized trials and large, retrospective studies. …
carcinoma for 20 years, supported by randomized trials and large, retrospective studies. …
Personalized 3D printed model of kidney and tumor anatomy: a useful tool for patient education
JC Bernhard, S Isotani, T Matsugasumi… - World journal of …, 2016 - Springer
Purpose To assess the impact of 3D printed models of renal tumor on patient’s understanding
of their conditions. Patient understanding of their medical condition and treatment …
of their conditions. Patient understanding of their medical condition and treatment …
Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery
…, R Avakian, M Crepel, JM Ferriere, JC Bernhard… - European urology, 2010 - Elsevier
BACKGROUND: The occurrence of positive surgical margins (PSMs) after partial nephrectomy
(PN) is rare, and little is known about their natural history. OBJECTIVE: To identify …
(PN) is rare, and little is known about their natural history. OBJECTIVE: To identify …
COVID‐19 and urology: a comprehensive review of the literature
…, V Patel, P Wiklund, RF Coelho, JC Bernhard… - BJU …, 2020 - Wiley Online Library
Objective To discuss the impact of COVID‐19 on global health, particularly on urological
practice and to review some of the available recommendations reported in the literature. …
practice and to review some of the available recommendations reported in the literature. …
Morbidity and clinical outcome of nephron-sparing surgery in relation to tumour size and indication
…, JS Lam, L Bellec, B Albouy, D Lopes, JC Bernhard… - European urology, 2007 - Elsevier
OBJECTIVE: To analyse through a large multicentre series, morbidity of nephron-sparing
surgery (NSS) in relation to tumour size and surgical indication. METHODS: The study included …
surgery (NSS) in relation to tumour size and surgical indication. METHODS: The study included …
Magnetic resonance imaging–transectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical …
…, S Palmer, T Matsugasumi, A Marien, JC Bernhard… - European urology, 2015 - Elsevier
Background Prostate biopsies targeted by elastic fusion of magnetic resonance (MR) and
three-dimensional (3D) transrectal ultrasound (TRUS) images may allow accurate …
three-dimensional (3D) transrectal ultrasound (TRUS) images may allow accurate …
Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker …
…, N Doumerc, P Paparel, JC Bernhard… - The Lancet …, 2022 - thelancet.com
Background We previously reported a 35-gene expression classifier identifying four clear-cell
renal cell carcinoma groups (ccrcc1 to ccrcc4) with different tumour microenvironments …
renal cell carcinoma groups (ccrcc1 to ccrcc4) with different tumour microenvironments …
Comparison of 1800 robotic and open partial nephrectomies for renal tumors
…, P Bigot, N Doumerc, JC Bernhard… - Annals of surgical …, 2016 - Springer
Background Only a few studies have compared the outcomes of robotic partial nephrectomy
(RPN) and open partial nephrectomy (OPN). This study aimed to compare perioperative and …
(RPN) and open partial nephrectomy (OPN). This study aimed to compare perioperative and …
MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array
…, N Rioux-Leclercq, M Sibony, JC Bernhard… - Clinical Cancer …, 2014 - AACR
Purpose: Papillary renal cell carcinomas (pRCC) are the most common nonclear cell RCC
subtype. Germline mutations of the MET oncogene at 7q31 have been detected in patients …
subtype. Germline mutations of the MET oncogene at 7q31 have been detected in patients …
Sunitinib alone or after nephrectomy for patients with metastatic renal cell carcinoma: is there still a role for cytoreductive nephrectomy?
…, S Oudard, B Laguerre, M Gross-Goupil, JC Bernhard… - European Urology, 2021 - Elsevier
Background The CARMENA trial in patients with metastatic renal cell carcinoma (mRCC)
demonstrated that treatment with sunitinib alone was noninferior to cytoreductive nephrectomy (…
demonstrated that treatment with sunitinib alone was noninferior to cytoreductive nephrectomy (…
